Want to see LGVN full AI Analyst Report?
Longeveron (LGVN) AI Stock Analysis
Longeveron
(NASDAQ:LGVN)
The score is primarily weighed down by weak financial performance (persistent large losses and heavy cash burn with a limited runway) and bearish technicals (price far below major moving averages with negative MACD). Offsetting factors include identifiable near-term clinical/regulatory catalysts and external validation noted on the earnings call, but valuation is hard to underwrite with negative earnings and no dividend support.
Longeveron Key Performance Indicators (KPIs)
Revenue by SegmentShows how Longeveron’s revenue is split across sources such as clinical trial services, grants, collaboration or licensing payments, and any product or service sales. A mix weighted toward grants and milestone payments means revenue can be lumpy and dependent on partnership timing; growing product or recurring revenue would indicate progress toward commercialization, steadier cash flow, and lower execution risk for investors.
Revenue has shifted from one‑off grant funding into lumpy, trial‑driven and contract‑manufacturing receipts, leaving top line volatile and materially weaker year‑over‑year; the 2024 contract‑manufacturing spike proved short‑lived and 2025 reliance fell back to clinical trial activity. With R&D/G&A spending up and cash constrained, management is effectively treating the upcoming HLHS readout and potential PRV/partnership monetization as the primary financing lever—so revenue today is a poor cushion and the stock is now catalyst‑driven, not growth‑driven.
The FlyLongeveron (LGVN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.42M
- Dividend Yield
- ―
- Average Volume (3M)
- 106.70K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 1.10
- Revenue Growth
- -42.74%
- EPS Growth
- 20.66%
- Country
- US
- Employees
- 38
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Longeveron Business Overview & Revenue Model
Company Description
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesse...
How the Company Makes Money
Longeveron does not have a widely documented, recurring commercial product revenue stream; null. As a clinical-stage biotech, its financial inflows have primarily come from financing activities (e.g., issuing equity/other securities) and, where appli...
Longeveron Earnings Call Summary
The call balanced meaningful scientific, regulatory, and validation milestones (upcoming ELPIS II readout, XPRIZE finalist award, high-profile publications, strong IP and expedited designations, and regulatory progress for PDCM) against material financial constraints (very low revenues, rising expenses, widening net loss, and a cash runway into Q4 2026). The business outlook is highly dependent on the imminent trial readout and the company's ability to secure partnerships or financing to extend the runway and commercialize programs.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company reiterated near‑term guidance that the ELPIS II Phase 2b top‑line readout is expected in September (database lock planned for August 31), with primary efficacy assessed by objective measures including all‑cause mortality, cardiac transplant‑free survival, occurrence of cardiac transplantation and specified adverse cardiac events (and additional exploratory endpoints such as RVEF); some patients already have up to five years of follow‑up and a long‑term extension is planned up to 10 years. On the financial side, Q2 revenues were $0.3M (down $29k, or 10% year‑over‑year), G&A was $3.2M (up $600k, or 23%; ~$400k legal, $200k personnel), R&D was $3.2M (up $200k, or 7%), net loss was $6.1M (up $1.1M, or 22%), and cash & cash equivalents were $10.1M as of June 30, 2026, which the company expects will fund operations into Q4 2026 under the current budget. Other metrics highlighted: Laromestrocel is covered by 52 issued patents and >60 pending, holds five FDA expedited designations (including RMAT, Fast Track, orphan and rare pediatric disease), the PDCM IND became effective July 2025 enabling advancement to a Phase 2 registrational trial, and the Aging‑related Frailty data helped secure an XPRIZE HealthSpan Milestone 2 finalist award (selected from >600 applicants across 58 countries) with a $1M award (XPRIZE total $101M over 7 years; grand prize up to $81M).
Longeveron Financial Statement Overview
Summary
Financials reflect a high-risk clinical-stage profile: very small and declining revenue (TTM revenue growth -2.385), extremely negative profitability (TTM EBIT margin ~-19.94; net margin ~-19.78), and heavy ongoing cash burn (TTM operating cash flow -$20.374M; TTM free cash flow -$20.659M). Low leverage is a relative positive (TTM debt-to-equity ~0.056), but equity/assets have swung materially and returns remain deeply negative (TTM ROE -2.23), reinforcing reliance on external funding.
Income Statement
18Very NegativeBalance Sheet
56NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.19M | 1.20M | 2.39M | 709.00K | 1.22M | 1.31M |
| Gross Profit | 828.00K | 803.00K | 1.88M | 221.00K | 497.00K | 590.00K |
| EBITDA | -22.66M | -21.48M | -15.02M | -20.47M | -17.94M | -16.13M |
| Net Income | -23.47M | -22.70M | -15.97M | -21.41M | -18.84M | -17.05M |
Balance Sheet | ||||||
| Total Assets | 15.49M | 10.26M | 25.56M | 12.08M | 27.41M | 42.77M |
| Cash, Cash Equivalents and Short-Term Investments | 10.08M | 4.66M | 19.23M | 5.36M | 19.66M | 35.04M |
| Total Debt | 581.00K | 824.00K | 1.45M | 2.04M | 2.60M | 3.14M |
| Total Liabilities | 5.08M | 4.59M | 3.67M | 5.34M | 6.91M | 5.31M |
| Stockholders Equity | 10.40M | 5.67M | 21.89M | 6.74M | 20.50M | 37.45M |
Cash Flow | ||||||
| Free Cash Flow | -20.66M | -18.89M | -14.86M | -19.30M | -14.82M | -10.95M |
| Operating Cash Flow | -20.37M | -18.64M | -13.87M | -19.00M | -13.97M | -9.64M |
| Investing Cash Flow | -305.00K | -595.00K | -640.00K | 8.19M | -677.00K | -10.70M |
| Financing Cash Flow | 20.42M | 4.67M | 28.79M | 5.26M | -509.00K | 45.17M |
Longeveron Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 1.80, below the 50-day MA of 3.63, and below the 200-day MA of 6.60, indicating a bearish trend. The MACD of -0.49 indicates Negative momentum. The RSI at 35.20 is Neutral, neither overbought nor oversold. The STOCH value of 70.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LGVN.
Longeveron Risk Analysis
Longeveron disclosed 91 risk factors in its most recent earnings report. Longeveron reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksLongeveron Peers Comparison
Overall Rating
PCSA52Neutral
IBIO42Neutral- LGVN42Neutral
EDSA40Underperform
CMMB38Underperform
FBLG37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PCSA | 52Neutral | $5.18M | -0.35 | -394.24% | ― | ― | 90.37% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| IBIO | 42Neutral | $48.68M | -2.53 | -47.92% | ― | -75.00% | 74.04% |
| LGVN | 42Neutral | $5.45M | -0.18 | -223.19% | ― | -42.74% | 20.66% |
| EDSA | 40Underperform | $32.97M | -1.35 | -124.21% | ― | ― | -27.34% |
| CMMB | 38Underperform | $8.55M | -1.15 | -70.81% | ― | ― | 56.99% |
| FBLG | 37Underperform | $6.13M | -0.17 | -536.78% | ― | ― | 22.10% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LGVN | Longeveron Inc. | 1.78 | -5.84 | -76.64% | |
| IBIO | Ibio Inc | 0.82 | -0.62 | -42.85% | |
| EDSA | Edesa Biotech | 2.28 | 0.59 | 34.91% | |
| CMMB | Chemomab Therapeutics Ltd. | 1.18 | -1.49 | -55.81% | |
| PCSA | Processa Pharmaceuticals, Inc. | 1.94 | -6.56 | -77.18% | |
| FBLG | FibroBiologics, Inc. | 0.99 | -6.42 | -86.63% |
Longeveron Corporate Events
Longeveron Highlights Positive HLHS Trial Safety Findings
PositiveOn October 26, 2026, Longeveron announced updated results from its ELPIS II Phase 2b trial of laromestrocel in 40 infants with hypoplastic left heart syndrome undergoing Stage II palliative surgery. The trial, run with National Institutes of Health f...
Longeveron Announces Chief Medical Officer Leadership Transition
NegativeOn October 7, 2026, Longeveron Inc. disclosed that Chief Medical Officer Dr. Nataliya Agafonova had informed management of her decision to step down from the role. Her resignation as CMO was scheduled to become effective on October 14, 2026, marking...
Longeveron ELPIS II Miss, Strategic Review and Refocus
NegativeOn September 16, 2026, Longeveron reported topline results from its ELPIS II Phase 2b trial of laromestrocel in 40 infants with hypoplastic left heart syndrome, showing the study failed to meet its primary endpoint of improving right ventricular ejec...
Longeveron Regains Nasdaq Compliance With Minimum Bid Price
PositiveLongeveron Inc. disclosed that on September 22, 2025 it received a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement, after its Class A common stock closed below $1.00 for thirty consecutive business days. The company was gran...
Longeveron Executes 1-for-10 Reverse Stock Split
NeutralOn July 1, 2026, Longeveron’s stockholders approved a reverse stock split proposal for the company’s Class A and Class B common stock, with the board setting a final ratio of 1-for-10 on July 31, 2026. The reverse split became effective a...
Longeveron Appoints New Chief Financial Officer Jhaveri
PositiveOn August 19, 2026, Longeveron announced the appointment of Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 17, 2026.Jhaveri, a veteran of biopharma and biotech finance with...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 26, 2026